Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NSD2 | O96028 | 1/20 | 0.31 |
| ▸ | MMP14 | P50281 | 1/20 | 0.31 |
| ▸ | CASP6 | P55212 | 1/20 | 0.31 |
| ▸ | CASP3 | P42574 | 1/20 | 0.30 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.30 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | NOS3 | P29474 | 1/20 | 0.30 |
| ▸ | NOS1 | P29475 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10001950 | 0.88 | THRB (0.36) | L3MBTL1NOS3NOS1 | |
| SCHEMBL1003965 | 0.87 | MAPT (0.40) | L3MBTL1 | |
| SCHEMBL1003967 | 0.87 | MAPT (0.40) | L3MBTL1 | |
| SCHEMBL2589702 | 0.78 | THRB (0.41) | L3MBTL1 | |
| SCHEMBL12107154 | 0.78 | THRB (0.41) | L3MBTL1 | |
| SCHEMBL10001951 | 0.78 | L3MBTL1 (0.41) | NSD2MMP14CASP6CASP3SENP7 | |
| SCHEMBL10001949 | 0.78 | L3MBTL1 (0.33) | L3MBTL1 | |
| SCHEMBL825301 | 0.75 | MAPT (0.49) | L3MBTL1 | |
| SCHEMBL29883561 | 0.75 | MAPT (0.49) | L3MBTL1 | |
| SCHEMBL825302 | 0.75 | MAPT (0.49) | L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8262948-B2 | Intraocular lenses with combinations of UV absorbers and blue light chromophores | NOVARTIS AG (CH) | 2012-09-11 | — | — | US | disclosed |
| US-8262948-B2 | Intraocular lenses with combinations of UV absorbers and blue light chromophores | NOVARTIS AG (CH) | 2012-09-11 | — | — | US | disclosed |
| US-8207244-B2 | Visible light absorbers for ophthalmic lens materials | NOVARTIS AG (CH) | 2012-06-26 | — | — | US | disclosed |
| US-8207244-B2 | Visible light absorbers for ophthalmic lens materials | NOVARTIS AG (CH) | 2012-06-26 | — | — | US | disclosed |
| WO-2011137142-A1 | INTRAOCULAR LENSES WITH COMBINATIONS OF UV ABSORBERS AND BLUE LIGHT CHROMOPHORES | NOVARTIS AG (CH) | 2011-11-03 | — | — | WO | disclosed |
| US-20110266505-A1 | INTRAOCULAR LENSES WITH COMBINATIONS OF UV ABSORBERS AND BLUE LIGHT CHROMOPHORES | ALCON INC. (CH) | 2011-11-03 | — | — | US | disclosed |
| US-20110266505-A1 | INTRAOCULAR LENSES WITH COMBINATIONS OF UV ABSORBERS AND BLUE LIGHT CHROMOPHORES | ALCON INC. (CH) | 2011-11-03 | — | — | US | disclosed |
| WO-2011005713-A2 | VISIBLE LIGHT ABSORBERS FOR OPHTHALMIC LENS MATERIALS | ALCON, INC. (CH) | 2011-01-13 | — | — | WO | disclosed |
| US-20110003910-A1 | VISIBLE LIGHT ABSORBERS FOR OPHTHALMIC LENS MATERIALS | ALCON, INC. (CH) | 2011-01-06 | — | — | US | disclosed |
| US-20110003910-A1 | VISIBLE LIGHT ABSORBERS FOR OPHTHALMIC LENS MATERIALS | ALCON, INC. (CH) | 2011-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003910-A1 | VISIBLE LIGHT ABSORBERS FOR OPHTHALMIC LENS MATERIALS | CRY1, CRY2, CRYAA | NSD2 2682/4885MMP14 2328/4885CASP6 4024/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.